drugset / Trial / NCT02658409

A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study

NCT02658409

Phase 3 Unknown 1630 enrolled Green Cross Corporation
RandomizedParallel-groupTriple-blindPrevention

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study.

Timeline

Start
2015-11
Primary completion
2015-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluarix™tetra Syringe Inj. Vaccine 0.5 ml Intramuscular
Subject GC3106 Vaccine 0.5 ml Intramuscular

Indications